Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford, and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2023. Even 15 years ago, companies like Radio Shack, AOL, Yahoo, and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.
As the years go by, some companies lose their luster, and others rise to the top of the markets. We've already seen this in the last few decades, with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega-trend will be that knocks Apple, Google, and Amazon off the top rankings of the S&P 500, but we know that companies don't stay on the S&P 500 forever.
We have identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they show negative earnings growth for the next several years. If you own any of these stocks, consider whether they still belong in your portfolio before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.
#1 - Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Read More
Trailing Twelve Months EPS: $11.36
2024 EPS Estimate: ($0.26)
2025 EPS Estimate: ($6.36)
- Current Stock Price
- $54.62
- P/E Ratio
- 4.8
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 4 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $52.33 (4.2% Downside)
CleanSpark, Inc operates as a bitcoin miner in the Americas. It owns and operates data centers that primarily run on low-carbon power. Its infrastructure supports Bitcoin, a digital commodity and a tool for financial independence and inclusion. The company was formerly known as Stratean Inc and changed its name to CleanSpark, Inc in November 2016.
Read More
2024 EPS Estimate: ($0.06)
2025 EPS Estimate: ($0.26)
- Current Stock Price
- $14.00
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $21.42 (53.0% Upside)
#3 - NexGen Energy (NYSE:NXE)
NexGen Energy Ltd., an exploration and development stage company, engages in the acquisition, exploration, and evaluation and development of uranium properties in Canada. It holds a 100% interest in the Rook I project that consists of 32 contiguous mineral claims totaling an area of 35,065 hectares located in the southwestern Athabasca Basin of Saskatchewan.
Read More
Trailing Twelve Months EPS: $0.15
2024 EPS Estimate: ($0.06)
2025 EPS Estimate: ($0.12)
- Current Stock Price
- $8.33
- P/E Ratio
- 55.5
- Consensus Rating
- Strong Buy
- Ratings Breakdown
- 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $11.00 (32.1% Upside)
Riot Platforms, Inc, together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through three segments: Bitcoin Mining, Data Center Hosting, and Engineering. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity.
Read More
Trailing Twelve Months EPS: $1.51
2024 EPS Estimate: ($0.31)
2025 EPS Estimate: ($0.68)
- Current Stock Price
- $12.15
- P/E Ratio
- 8.0
- Consensus Rating
- Buy
- Ratings Breakdown
- 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $16.35 (34.6% Upside)
#5 - Lumen Technologies (NYSE:LUMN)
Lumen Technologies, Inc, a facilities-based technology and communications company, provides various integrated products and services to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers dark fiber, edge cloud services, internet protocol, managed security, software-defined wide area networks, secure access service edge, unified communications and collaboration, and optical wavelengths services; ethernet and VPN data networks services; and legacy services to manage cash flow, including time division multiplexing voice, private line, and other legacy services, as well as sells communication equipment, and IT solutions.
Read More
Trailing Twelve Months EPS: ($2.17)
2024 EPS Estimate: ($0.38)
2025 EPS Estimate: ($0.94)
- Current Stock Price
- $7.55
- Consensus Rating
- Reduce
- Ratings Breakdown
- 0 Buy Ratings, 5 Hold Ratings, 3 Sell Ratings.
- Consensus Price Target
- $4.02 (46.7% Downside)
#6 - Patterson-UTI Energy (NASDAQ:PTEN)
Patterson-UTI Energy, Inc, through its subsidiaries, engages in the provision of contract drilling services to oil and natural gas operators in the United States and internationally. It operates through three segments: Drilling Services, Completion Services, and Drilling Products. The Contract Drilling Services segment provides contract and directional drilling services in onshore oil and natural gas basins, as well as engages in the service and re-certification of equipment for drilling contractors, and provision of electrical controls and automation to the energy, marine and mining industries.
Read More
Trailing Twelve Months EPS: ($2.19)
2024 EPS Estimate: $0.12
2025 EPS Estimate: ($0.08)
- Current Stock Price
- $8.13
- Dividend Yield
- 3.98%
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 10 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $11.88 (46.1% Upside)
#7 - Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Read More
Trailing Twelve Months EPS: ($0.28)
2024 EPS Estimate: ($0.30)
2025 EPS Estimate: ($0.33)
- Current Stock Price
- $18.62
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $34.75 (86.6% Upside)
GitLab Inc, through its subsidiaries, develops software for the software development lifecycle in the United States, Europe, and the Asia Pacific. It offers GitLab, a DevOps platform, which is a single application that leads to faster cycle time and allows visibility throughout and control over various stages of the DevOps lifecycle.
Read More
Trailing Twelve Months EPS: ($2.34)
2024 EPS Estimate: ($0.41)
2025 EPS Estimate: ($0.52)
- Current Stock Price
- $62.15
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 22 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $66.38 (6.8% Upside)
IonQ, Inc engages in the development of general-purpose quantum computing systems in the United States. It sells access to quantum computers of various qubit capacities. The company makes access to its quantum computers through cloud platforms, such as Amazon Web Services (AWS) Amazon Braket, Microsoft's Azure Quantum, and Google's Cloud Marketplace, as well as through its cloud service.
Read More
Trailing Twelve Months EPS: ($0.81)
2024 EPS Estimate: ($0.86)
2025 EPS Estimate: ($1.15)
- Current Stock Price
- $28.89
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $17.50 (39.4% Downside)
#10 - Viking Therapeutics (NASDAQ:VKTX)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
Trailing Twelve Months EPS: ($0.93)
2024 EPS Estimate: ($0.98)
2025 EPS Estimate: ($1.44)
- Current Stock Price
- $51.53
- Consensus Rating
- Buy
- Ratings Breakdown
- 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $109.80 (113.1% Upside)
#11 - Brookfield Renewable (NYSE:BEPC)
Brookfield Renewable Corporation owns and operates a portfolio of renewable power and sustainable solution assets primarily in the United States, Europe, Colombia, and Brazil. It operates hydroelectric, wind, solar, and distributed energy and sustainable solutions with an installed capacity of approximately 19,161 megawatts.
Read More
Trailing Twelve Months EPS: ($0.82)
2024 EPS Estimate: ($1.04)
2025 EPS Estimate: ($1.62)
- Current Stock Price
- $31.34
- Dividend Yield
- 4.72%
- Consensus Rating
- Hold
- Ratings Breakdown
- 0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $32.00 (2.1% Upside)
MARA Holdings, Inc operates as a digital asset technology company that mines digital assets with a focus on the bitcoin ecosystem in United States. The company was formerly known as Marathon Digital Holdings, Inc and changed its name to MARA Holdings, Inc in August 2024. MARA Holdings, Inc was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.
Trailing Twelve Months EPS: $0.79
2024 EPS Estimate: ($0.72)
2025 EPS Estimate: ($0.75)
- Current Stock Price
- $22.63
- P/E Ratio
- 28.6
- Consensus Rating
- Hold
- Ratings Breakdown
- 4 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $22.57 (0.3% Downside)
#13 - Frontier Communications Parent (NASDAQ:FYBR)
Frontier Communications Parent, Inc, together with its subsidiaries, provides communication and technology services in the United States. It offers broadband, video, voice, and other value-added services. The company also provides data and Internet, including broadband networking services; data-based voice over internet protocol, unified communications, long-distance, and voice messaging services; video services under the Frontier TV brand; access services; hardware and network solutions; and packages of services.
Read More
Trailing Twelve Months EPS: ($0.75)
2024 EPS Estimate: ($0.83)
2025 EPS Estimate: ($0.98)
- Current Stock Price
- $34.70
- Consensus Rating
- Hold
- Ratings Breakdown
- 3 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $35.31 (1.8% Upside)
EchoStar Corporation, together with its subsidiaries, provides networking technologies and services worldwide. The company operates in four segments: Pay-TV, Retail Wireless, 5G Network Deployment, Broadband and Satellite Services. The Pay-TV segment offers a direct broadcast and fixed satellite services; designs, develops, and distributes receiver system; and provides digital broadcast operations, including satellite uplinking/downlinking, transmission and, other services to third-party pay-TV providers; and multichannel, live-linear and on-demand streaming over-the-top internet-based domestic, international, Latino, and Freestream video programming services under the DISH and SLING brand names.
Read More
Trailing Twelve Months EPS: ($9.16)
2024 EPS Estimate: ($1.83)
2025 EPS Estimate: ($4.19)
- Current Stock Price
- $23.43
- Consensus Rating
- Hold
- Ratings Breakdown
- 1 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $19.25 (17.8% Downside)
#15 - Janux Therapeutics (NASDAQ:JANX)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Read More
Trailing Twelve Months EPS: ($1.17)
2024 EPS Estimate: ($1.34)
2025 EPS Estimate: ($1.92)
- Current Stock Price
- $48.96
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $66.44 (35.7% Upside)
#16 - Roivant Sciences (NASDAQ:ROIV)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Trailing Twelve Months EPS: $5.65
2024 EPS Estimate: ($1.14)
2025 EPS Estimate: ($1.25)
- Current Stock Price
- $11.49
- P/E Ratio
- 2.0
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $17.93 (56.0% Upside)
#17 - Edgewise Therapeutics (NASDAQ:EWTX)
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Read More
Trailing Twelve Months EPS: ($1.50)
2024 EPS Estimate: ($1.45)
2025 EPS Estimate: ($1.80)
- Current Stock Price
- $31.95
- Consensus Rating
- Buy
- Ratings Breakdown
- 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $38.40 (20.2% Upside)
#18 - MoonLake Immunotherapeutics (NASDAQ:MLTX)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Trailing Twelve Months EPS: ($1.29)
2024 EPS Estimate: ($1.74)
2025 EPS Estimate: ($2.54)
- Current Stock Price
- $49.82
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 8 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $79.00 (58.6% Upside)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Read More
Trailing Twelve Months EPS: ($0.71)
2024 EPS Estimate: ($1.49)
2025 EPS Estimate: ($1.73)
- Current Stock Price
- $87.22
- Consensus Rating
- Buy
- Ratings Breakdown
- 14 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $103.08 (18.2% Upside)
#20 - BridgeBio Pharma (NASDAQ:BBIO)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Read More
Trailing Twelve Months EPS: ($2.41)
2024 EPS Estimate: ($2.58)
2025 EPS Estimate: ($3.52)
- Current Stock Price
- $23.04
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $47.57 (106.5% Upside)
More Investing Slideshows:
